Navigation Links
Paul J. Mirabella, President and CEO of Naviscan PET Systems Inc., Joins GenVault's Board of Directors
Date:6/12/2008

CARLSBAD, Calif., June 12 /PRNewswire/ -- GenVault Corporation today announces Paul J. Mirabella, Chairman and CEO of Naviscan PET Systems Inc., has joined its Board of Directors. Mr. Mirabella has more than 30 years of experience in diagnostic imaging with GE Healthcare where he held leadership roles in technology, marketing and global business management. Drawing on this substantial background in diagnostics and the healthcare market, he will help guide GenVault's entry into new biosample management markets as well as streamline operational efficiencies.

"Mr. Mirabella's deep business experience and understanding of the healthcare industry will be extremely valuable as we develop new technologies to expand our addressable markets. We are extremely honored to welcome Mr. Mirabella as a key member of the GenVault team," said David Wellis, CEO of GenVault.

"Biosamples are the conduit of information from the patient to clinicians and researchers. Advances in the handling of these samples will result in more efficient diagnosis, therapy development and ultimately a healthier population. I'm pleased to participate in building such a critical solution," said Mr. Mirabella.

Mr. Mirabella's previous experience includes leadership roles at GE Healthcare in ultrasound, computed tomography (CT), magnetic resonance, and sales and services. Mr. Mirabella holds four patents in CT and has participated in a variety of successful global product launches. Prior to joining Naviscan, he was President and CEO of Global Diagnostic Imaging, while retaining responsibility for the commercial leadership of sales, marketing and services in the Americas. Mr. Mirabella obtained degrees in aerospace engineering and applied mechanics from Polytechnic Institute of New York and a Masters in mechanical engineering from the University of Central Florida. He is a graduate of the GE Business Management Program accredited by the University of Wisconsin-Whitewater.

Mr.
'/>"/>

SOURCE GenVault Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Lillys Connelly Appointed to the Presidents Commission on White House Fellowships
2. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
3. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
4. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
5. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
6. Abt Associates Names Richard Small Vice President and Chief Financial Officer
7. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
8. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
9. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
10. Board Certified Dermatologist and President-Elect of the Dermatologic Society of Greater New York, Dr. Lance H. Brown Takes His Comprehensive Practice to East Hampton, NY
11. Michael V. Novinski, Emisphere President/CEO Featured in the Wall Street Transcript
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3